1E10 anti-idiotype vaccine in non-small cell lung cancer: Experience in stage IIIb/IV patients.

Abstract

Conventional treatment of non-small cell lung cancer (NSCLC) has apparently reached a plateau of effectiveness in improving the survival of the patients. For that reason the search for new therapeutic strategies in this type of tumor is justified. 1E10 is an anti-idiotype murine monoclonal antibody (Ab2 MAb) specific to P3 Ab1 MAb, which reacts with NeuGc-containing gangliosides, sulfatides and with antigens expressed in some tumors, including those from the lung. We report the treatment with aluminum hydroxide-precipitated 1E10 MAb of 34 stage IIIb and 37 stage IV NSCLC patients. These patients were treated with the anti-idiotype vaccine, after received standard chemotherapy and radiotherapy, in a compassionate-use basis study. Patients received five bi-weekly injections of 1 mg of 1E10/Alum, other 10 doses at 28-day intervals and later the patients who maintained a good performance status continued to be immunized at this same time interval. No evidence of unexpected or serious adverse effects was reported. The median survival time of the 56 patients who entered the study with partial response or disease stabilization and with a PS 1 after the first line of chemo/radiotherapy, was 11.50 months from starting vaccination. In contrast, the median survival time calculated for patients who started vaccination with progressive disease and/or a PS2 was 6.50 months.

Characterization of the Antibody Response against NeuGcGM3 Ganglioside Elicited in Non-Small Cell Lung Cancer Patients Immunized with an Anti-Idiotype Antibody

“…More recently we performed a clinical study in NSCLC patients that showed encouraging clinical benefits (28). We now report the immune response elicited in 20 advanced NSCLC patients treated with 1E10 mAb, and demonstrate the induction of Abs that are Id We hypothesize 1E10 Id vaccination could induce an idiotypic cascade, which would amplify the Ag-specific immune response to a tumor-associated neo-self ganglioside Ag.…”

Cytolytic tests with hyperimmune patient sera is a good prognostic tool in racotumomab immunotherapy in advanced non-small cell lung cancer

“…They termed this process as oncotic necrosis [17] . Neugcgm3 ganglioside-based vaccines have been tested in several Phase II-III studies in nonsmall cell lung cancer and melanoma [18][19][20][21] . racotumomab is currently registered in Cuba and Argentina in nonsmall cell lung cancer as a second line treatment after first line chemotherapy.…”

Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?

“…Those patients who had ECOG performance status 1 (PS1) and started the experimental treatment after a PR or stabilization with first-line treatments had a more consistent benefit in OS (11.50 months; 95% CI: 7.97-15.03) and a 1-year survival of 39%. Toxicity profile was good, and the most common side effects were local reaction at the injection site and fever [68]. Currently, a prospective, randomized, openlabel, parallel-group, multicenter Phase III study is still recruiting patients.…”